1. How dangerous is varicella? Why should children be vaccinated early?
Varicella is a common acute infectious disease in children, caused by the Varicella-Zoster virus (VZV), and is highly transmissible via respiratory droplets or direct contact with fluid from vesicular lesions. The disease affects approximately 80–90% of children aged 1–10 years (preschool and primary school age), particularly those without prior natural immunity or vaccination. Notably, the virus can be transmitted even before the onset of rash, making outbreaks in communities—especially in schools and residential settings—difficult to control. Among susceptible populations, the transmission rate can reach up to 90% [1], [2].
Following an incubation period of 10 to 21 days, children typically develop symptoms such as fever, fatigue, and loss of appetite, followed by a generalized vesicular rash. Although many cases are mild, varicella may lead to serious complications, including pneumonia, encephalitis, meningitis, secondary bacterial skin infections, or long-term sequelae. In addition, the virus can remain latent in the body and reactivate later in life as herpes zoster (shingles). According to the World Health Organization (WHO), vaccination is the most effective measure to prevent the disease and reduce complications [2].
Image of varicella
2. BARYCELA varicella vaccine
In the context of increasing demand for disease prevention, the BARYCELA varicella vaccine is considered a modern immunisation solution that meets international standards for quality and safety. This is a live attenuated varicella vaccine, developed from the Varicella-Zoster virus MAV/06 strain, capable of inducing active immunity against varicella [3].
The vaccine is researched and manufactured by GC Biopharma (Republic of Korea), one of Asia’s leading vaccine manufacturers with over 50 years of experience in biopharmaceuticals. For varicella vaccines, the MAV/06 strain platform has been widely used for over 30 years in more than 30 countries, with over 30 million doses administered globally. The manufacturing process has also been further optimised to enhance product stability and safety [4].
BARYCELA inj. vaccine
3. Why is the BARYCELA varicella vaccine trusted?
BARYCELA stands out due to its advanced manufacturing process, which complies with Good Manufacturing Practice (GMP) standards and stringent aseptic procedures in alignment with US FDA recommendations. A key distinguishing feature is that the vaccine does not contain antibiotics, thereby reducing the risk of hypersensitivity reactions and aligning with current immunisation safety trends [4].
In addition, the vaccine has achieved WHO Prequalification (WHO-PQ), ensuring full compliance with global standards for quality, safety, and efficacy. Clinical studies have demonstrated that BARYCELA achieves immunogenicity rates above 95% and a safety profile comparable to reference vaccines [4], while maintaining high stability with a minimum potency of ≥ 3800 PFU throughout its shelf life [5].
4. BARYCELA vaccination schedule: When should it be administered for optimal protection?
BARYCELA is indicated for children aged 12 months to 12 years to provide active immunisation against varicella. The recommended schedule consists of two doses, with the first dose administered from 12 months of age and the second dose given 3 months after the first (minimum interval of 4 weeks) to enhance protective efficacy [6].
The vaccine is administered as a 0.5 mL dose after reconstitution and is given subcutaneously in the outer aspect of the upper arm. Adherence to the recommended schedule and professional guidelines plays a critical role in ensuring long-term immune protection [3].
Vaccination is a safe and effective preventive measure
5. Is BARYCELA safe? What should be considered before vaccination?
Like other vaccines, BARYCELA may cause some post-vaccination reactions; however, most are mild and self-limiting. These may include injection-site pain and mild fever, which are generally uncommon and transient. Hypersensitivity reactions are rare [3].
The vaccine is contraindicated in individuals with a history of severe allergic reactions to any component of the vaccine, immunocompromised individuals, and pregnant women. Vaccination should be deferred in patients with acute febrile illness. It should also be noted that the vaccine must not be administered intravenously or intramuscularly.
6. Strict storage standards to ensure vaccine efficacy
To maintain its quality and effectiveness, BARYCELA must be stored at 2–8°C, protected from light, and must not be frozen. After reconstitution, the vaccine should be used within 30 minutes to ensure optimal efficacy. Strict adherence to cold chain storage and transportation requirements is essential throughout the immunisation system.
7. NAVIVA Group – A trusted distributor of BARYCELA in Vietnam
In Viet Nam, NAVIVA Group is the authorised distributor of the BARYCELA varicella vaccine. With more than 22 years of experience in vaccines and medical biological products, NAVIVA Group has established a logistics system that complies with GDP/GSP standards, along with a nationwide distribution network.
The combination of strong operational capacity and partnerships with international manufacturers enables NAVIVA Group to ensure a stable supply, consistent product quality, and effective support for vaccination centres. This plays a key role in improving vaccine coverage and protecting public health.
8. Proactive varicella vaccination – A sustainable step in protecting children’s health
As varicella remains a common disease with potential complications, early proactive vaccination is an essential strategy to protect children’s health. With a strong scientific foundation, advanced manufacturing processes, and internationally recognised standards, BARYCELA represents a reliable option in disease prevention strategies.
NAVIVA GROUP
“Community health is our happiness!”
Contact Information:
NAM HUNG VIET Vaccine & Biological Products Joint Stock Company
Address: No. 89, Nguyen Thi Thap Street, Him Lam Area, Tan Hung Ward, Ho Chi Minh City
Phone: 028 2223 2425
TUONG KHUE Pharmaceutical Joint Stock Company
Address: 33 Le Lai Street, Hai Chau Ward, Da Nang City
Phone: 0236 3538 666
WINBIO Joint Stock Company
Address: K7TT1 – SH19, Starlake Urban Area, Xuan Dinh Ward, Hanoi Capital
Phone: 024 3795 6789
References:
[1] Vietnam Ministry of Health, Infectious Diseases, Medical Publishing House.
[2] Centers for Disease Control and Prevention, “Varicella (Chickenpox),” 2024.
[3] GC Biopharma, “BARYCELA inj. Product Information,” 2025.
[4] World Health Organization, “WHO Prequalification of BARYCELA Vaccine,” 2023.
[5] S. Y. et al., “Immunogenicity and safety of varicella vaccine,” Vaccine, Elsevier, 2021.
[6] Vietnam Society of Preventive Medicine, “Recommended Immunization Schedule for All Ages in Vietnam,” 2026.
